Background: Higher awareness could translate into better care for patients with breast cancer than for those with other cancers. This study examines utilization of two key oncology services across cancer sites: consultation with an oncologist and receipt of treatment.
codes: c50.0-c50.6, c50.8, and c50.9], colon (ICD-O [25] codes: c18.0 and c18.2-c18.9), rectal (ICD-O [25] codes: c19.9 and c20.9), or lung (ICD-O [25] codes: c34.0-c34.3, c34.8, and c34.9) cancer were identified from the Alberta Cancer Registry. Only the histologies of adenocarcinoma for colorectal cancers and non-small cell for lung cancers were included. Patients were excluded if they were (i) treated outside of the province, (ii) diagnosed with another cancer within the preceding or subsequent 6 months of their diagnosis (may interfere with expected treatment), (iii) died within 1 week of their diagnosis (no opportunity to receive expected treatment), or (iv) did not have a cancer stage for which at least one of chemotherapy, radiation therapy, or hormonal therapy was an 'expected' treatment.
'Expected' treatment, including both curative and palliative intent, was defined as treatment that was recommended in guidelines in 2005 as standard treatment for patients with a particular cancer stage or for which the majority of patients would be expected to benefit. According to treatment guidelines in 2005 [10] [11] [12] [13] , most patients with stage I-IV breast cancer should or may be treated with hormonal therapy, chemotherapy, or radiation therapy or a combination of the three; patients with stage III-IV colon, stage II-IV rectal, or stage IB-IV lung cancer should or may be treated with chemotherapy and/or radiation therapy.
data source for clinical and demographic information
Demographic and treatment information including date and stage of diagnosis, patient age at diagnosis, region of residence at diagnosis, initial treatment modalities, and start dates of each were obtained from the Alberta Cancer Registry. Cancer stage was determined using the American Joint Committee on Cancer (version 6) [26] staging rules. Initial treatment includes all treatment modalities given at the time of diagnosis to the primary tumor site; it does not include treatment given for disease progression or treatment given to metastatic sites. data source for oncology consultations and treatment to metastatic sites
The cancer electronic medical record was used to identify whether a consultation with an oncologist occurred and the first date of radiation therapy or chemotherapy that was given to a metastatic site (i.e. palliation for stage IV patients). Based on previous quality assurance checks, consultations that occurred within 6 months of diagnosis and/or within 3 months of surgery were considered to be consultations to discuss initial treatment options. The progress notes were manually reviewed to confirm whether or not a consultation had occurred for all cases in which a consultation within the aforementioned time frame was not found in the electronic system.
statistical analysis
The primary outcomes of the study were as follows: (i) having a consultation with an oncologist to discuss treatment options and (ii) receiving expected chemotherapy, radiation therapy, or hormonal therapy. In the first stage of analysis, univariate associations of potential explanatory variables with having a consultation and treatment were assessed in the entire eligible patient cohort and stratified by tumor site. Age was categorized using arbitrary cut-off points of 50, 60, 70, and 80 years at diagnosis. For regional comparisons, patient residence at diagnosis was categorized into five areas: Northern, Edmonton and area, Central, Calgary and area, and Southern. The Northern, Central, and Southern regions comprise rural and/or remote regions that have small cancer facilities that provide consultations and/or chemotherapy close to home. Edmonton and Calgary are large urban cities that provide all major cancer services.
Percentage of patients who had a consultation to discuss treatment options and, of those who attended the consultation, the percent who received treatment were compared across tumor sites and by potential explanatory variables. P values were calculated using chi-square tests [27] to assess the variation by age, stage, and region across cancer sites. The Cochran-Armitage trend test [28] was used to test for statistical association of increasing age and having a consultation and receiving treatment. The age effect on the outcomes was also assessed graphically by fitting a logistic regression model including age as a cubic spline with four knots [29] for each cancer site.
In the second stage of analysis, multivariable log-binomial regression was conducted to examine associations of the potential explanatory variables with not having a consultation and not receiving treatment after consultation. This analysis provides estimates of relative risk (RR), which are easier to interpret than odds ratios obtained from the more traditional logistic regression analysis. The COPY method [30] was used to overcome convergence issues in the log-binomial model. P values and 95% confidence intervals (CIs) were calculated using the large-sample approximation of the regression. All analyses were carried out using statistical software SAS 9. 
results
There were 4886 patients diagnosed with invasive breast, colon, rectal, or non-small-cell lung cancer in Alberta in 2005. The following numbers of patients were excluded for each exclusion criterion: 250 were not Alberta residents or were treated outside of the province, 74 colorectal patients had histology other than adenocarcinoma, 142 patients had another cancer within 6 months of diagnosis, 74 patients died within a week of diagnosis, and 788 did not have the disease stage of interest. A total of 3558 patients were, therefore, included in the study: 1673 had stage I-IV breast cancer (96% of all breast cancer patients), 404 had stage III-IV colon cancer (48% of all colon cancer patients), 357 had stage II-IV rectal cancer (74% of all rectal cancer patients), and 1124 had stage IB-IV lung cancer (87% of all lung cancer patients). Table 1 summarizes the characteristics of the patients included in the study, overall and by cancer site; 51% of patients with breast cancer are younger than 60 years compared with 20%-30% of the patients with other cancers. Over half of the lung cancer patients (57%) were diagnosed with stage IV disease, whereas just under half of the breast cancer patients were diagnosed with stage I disease (47%). Most lung cancer patients do not have surgery (87%), whereas most patients with breast, colon, or rectal cancer do have surgery (81%-94%). Table 2 shows the percentage of patients who had a consultation and subsequently received treatment and the relationship to patient demographics, overall and for each cancer site. Of the patients who received chemotherapy or radiation therapy, 137 stage IV patients (7 breast, 13 colon, 3 rectal, and 114 lung) received it only for palliation of metastatic disease. In general, there are significant differences in the proportion of patients who had a consultation and treatment by cancer site. Breast cancer patients were most likely to have a consultation and lung cancer patients the least likely, 92% versus 77%, respectively. Patients with breast cancer were the most likely to receive treatment after having a consultation and patients with colon cancer the least likely, 89% versus 72%, respectively.
There is also large variation in the outcomes by age, stage, region of residence, and surgery status. A common and significant trend across cancer sites was that age was inversely related to having a consultation (test for trend P < 0.0001 for all cancer sites) and to receiving treatment (test for trend P < 0.0001 for all cancer sites). Except for patients with colon cancer, those living in Southern Alberta were least likely to have a consultation. If a patient had a consultation, however, region of residence was not associated with receipt of treatment. Disease stage is significantly associated with having a consultation when all cancer sites are combined (P < 0.0001; range 80%-90%); however, when assessed by cancer site, stage is only related to having a consultation for rectal cancer (P = 0.05). Figure 1A and B illustrate the nonlinear relationship between patient age and probability of having a consultation and subsequently receiving treatment, respectively, and the variation of the relationships across cancer sites. The most striking findings are (i) the large age effect for lung cancer patients in having a consultation and the much smaller age effect for them to receive treatment relative to the respective age effects for the other cancers and (ii) the similarity of the age effect for patients with colon and rectal cancers in terms of probability of having a consultation but the subsequent difference with respect to receiving treatment; the likelihood of receiving treatment for patients with colon cancer diminishes faster with age than for those with rectal cancer, even though the patients and recommended treatments are similar. Table 3 shows, for each cancer site, the adjusted RRs and the corresponding 95% CIs of patient demographics to not having a consultation and not receiving subsequent treatment. Consistent with the unadjusted analysis ( Table 2) , age was the strongest factor related to both outcomes across all cancer sites; the strength of the association varies by cancer site, consistent with Figure 1 . Region of residence was also significantly related to not having a consultation for all tumor sites except colon. Only patient age and surgery status were related to whether patients with colon cancer had a consultation. Patients with stage III rectal or lung cancer were most likely to have a consultation: RR = 0.6, CI = 0.3-1.1, and RR = 0.7, CI = 0.5-0.9, respectively, relative to stage IV.
The RR of not having a consultation adjusted for patient age and region of residence for patients with colon, rectal, or lung cancer relative to breast cancer was 1.6, 1.6, and 2.1, respectively (P < 0.0001) (not shown in Table 3 ). The RR of not receiving treatment after having a consultation adjusted for patient age and disease stage for patients with colon, rectal, or lung cancer relative to breast cancer is 4.0, 2.0, and 1.6, respectively (P < 0.0001) (not shown in Table 3 ).
discussion
The purpose of this study was to examine utilization of the two key oncology services that should lead to improved survival or improved quality of remaining life: consultation with an oncologist and receipt of treatment, and identify factors related to not receiving these services for patients with breast, colon, rectal, or lung cancer. Of the 3558 patients included, 3058 (86%) had a consultation with an oncologist to discuss treatment options. Of those who had a consultation, 2625 (74% Table 1 
Characteristics
All sites Breast, stage I-IV Colon, stage III-IV Rectal, stage II-IV Lung, stage IB-IV n % a n % a n % a n % a n % Our results show slightly higher utilization rates compared with studies conducted in the United States using the Surveillance, Epidemiology, and End Results (SEER) data. Depending on tumor site and stage, the percentage of patients who saw an oncologist are 4%-12% higher in Alberta than in the SEER data [31] [32] [33] [34] and overall percent receiving treatment is 4%-16% higher [35] [36] [37] . Comparing across the studies conducted with SEER data, however, results are consistent with ours in that a much higher percentage of patients with breast cancer have consultations with oncologists and receive treatment than those with colon, rectal, or lung cancer [31] [32] [33] [34] [35] [36] [37] .
There are few studies that have compared receipt of oncology services across cancer sites; however, they are consistent in their finding that breast cancer patients are more likely to receive treatment according to guidelines than patients with other cancers [38, 39] . The only exception to this is a study conducted by Harlan et al. [40] that found similar percentages of patients with early-stage breast, colon, and lung cancers receiving care according to guidelines; however, there was large variation by type of insurance; this barrier to health care does not exist in Canada.
In clinical practice, the majority of breast cancer patients are well enough to receive some type of curative therapy due to the disease stage at diagnosis and the availability of relatively less toxic and effective hormonal therapy. Physicians, therefore, may have few reservations in referring patients with breast cancer to an oncologist. In contrast, lung cancer patients are older at diagnosis and present at a later incurable disease stage, often with comorbidities, and have fewer curative treatment options. There is clear evidence that lung cancer patients with decreased performance status (PS) and/or nutritional status do not benefit from chemotherapy as curative treatment [41, 42] . A large proportion of lung cancer patients, however, are diagnosed with stage IV disease, for which palliative radiation therapy is an effective way to control symptoms and relieve pain caused by metastases. It is possible, however, that P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.001 P < 0.0001 c P < 0.0001 c P < 0.0001 c P < 0.0001 c P < 0.0001 c P < 0.0001 c P < 0.0001 c P < 0.0001 c P < 0. 315 (62) 216 (69) (42) 142 (74) 108 (76) 45 (56) 15 (33) 27 (57) 14 (52) 101 (53) 79 (78) Region P < 0.0001 P = 0.88 P < 0.0001 P = 0.08 P = 0.77 P = 0.92 P = 0.01 P = 0.69 P = 0.001 P = 0.12 Edmonton 1033 (87) 881 (85) (74) (61) 99 (74) 93 (94) 28 (78) 22 (79) 16 (70) 14 (88) 59 (62) 45 (76) Stage P < 0.0001 P = 0.01 P = 0.27 P < 0.0001 P = 0.41 P = 0.83 P = 0.05 P = 0.52 P = 0.22 (95) 176 (82) 127 (72) 73 (86) 61 (84) 491 (77) 433 (88) Surgery P < 0.0001 P = 0.54 P = 0.005 P = 0.20 P < 0.0001 P = 0.97 P = 0.37 
Annals of Oncology original article
a large portion of physicians in the community are less aware of the benefits of radiation therapy as a form of effective palliative treatment; other barriers may also exist that limit utilization of palliative radiation therapy [43, 44] . Although patients with lung cancer who were older than 80 years of age were the least likely to have a consultation with an oncologist (53%), if they did, they were the most likely cancer patients in that age-group to receive treatment (78%), suggesting that only those that are relatively well and strongly desiring treatment are referred. Relationship of age and probability of having a consultation with an oncologist and subsequent receipt of chemotherapy, radiation therapy, or hormonal therapy. original article
Annals of Oncology
Older age is often associated with lower PS and/or presence of comorbidities [45, 46] , both factors that may affect receipt of treatment. A limitation to this study is the lack of information regarding PS and comorbidities in the study population. Previous studies, however, have shown that older patients are less likely to receive treatment according to guidelines than younger patients, after adjusting for comorbidities and/or PS [36, [47] [48] [49] [50] [51] [52] . Furthermore, these studies have found little change in the unadjusted risk estimates for age relative to those adjusted for comorbidities [36, [47] [48] [49] [50] [51] [52] . This suggests that the estimates for the effects of age found in this study would not change appreciably even if comorbidities and/or PS were included in the multivariate models.
A surprising finding was that patients with colon cancer were, overall, the least likely to receive treatment. This is striking for at least three reasons: (i) patients with rectal and colon cancers are very similar with respect to demographics and comorbidities; therefore, barriers to consultation should be similar; (ii) colon cancer surgery is much simpler than rectal cancer surgery; therefore, recovery should be faster and recovery rates higher lending more patients eligible for adjuvant chemotherapy; and (iii) adjuvant treatment options with curative intent have been standard for 20 years for colon cancer and are less complex compared with rectal cancer. One possible explanation for the discrepancy between colon and rectal cancer treatment rates may be that surgeons who carry out rectal cancer surgery are more aware of rectal cancer treatment guidelines and are, therefore, more likely to refer patients to an oncologist than surgeons who carry out colon cancer surgery, which can be carried out by a general surgeon. Reasons for these discrepancies in patterns of consultations with oncologist and subsequent treatment need further examination to eliminate disparities in care across cancer sites.
Breast cancer awareness is very high compared with other cancers due to extensive marketing and fund-raising campaigns. Breast cancer fund-raising programs and events are plentiful across North America [53] [54] [55] [56] [57] [58] [59] . There are dedicated programs and fund-raisers for colorectal [60] [61] [62] [63] and lung [64] [65] [66] [67] cancers; however, they are not nearly as prevalent as those for breast cancer. It is possible that higher awareness has also played a key role in the higher consultation and treatment rates for patients with breast cancer. This may be due to increased awareness and education of the patients themselves and/or of the family doctors and general practitioners responsible for initiating diagnosis and referral of patients to appropriate specialists.
A prerequisite for improving utilization of cancer services is enhanced physician and public/patient awareness of the value of the services in extending and/or improving a cancer patient's life. Decision makers, cancer service providers, and cancer fund-raisers need to increase their efforts in developing and implementing successful cancer education/awareness programs and activities directed at all cancer patients (not just breast cancer patients), the public, and referring physicians to address the current disparities in access to and utilization of quality cancer care that exist based on tumor site. We are currently implementing a program directed at colorectal surgeons to increase referrals to oncologists. Initiating such practical measures should result in an increase in the percentage of patients who receive treatment consistent with guidelines. We will monitor both the rate of consultation and the rate of guideline-consistent treatment to evaluate the success of the intervention.
acknowledgements
The authors thank Angela Bella for assistance in the formatting of tables and references of this article. 
